What Autolus does

Autolus Therapeutics plc is a UK-domiciled (London), NASDAQ-listed (AUTL) clinical-to-commercial biopharmaceutical company founded in 2014 by Dr Martin Pule and spun out of University College London. The company designs and manufactures autologous CAR T cell therapies using a proprietary advanced cell programming platform centred on Chimeric Antigen Receptors, proprietary viral vectors, and semi-automated cell manufacturing processes. Its sole commercial product is AUCATZYL (obecabtagene autoleucel / obe-cel), a CD19-directed CAR T therapy approved by the U.S. FDA in 2024, the UK MHRA in 2025, and the European Commission in 2025 for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL); the UK commercial launch occurred in January 2026 following a positive NICE recommendation. Underlying the commercial business is a pipeline of next-generation CAR T candidates (AUTO1/22, AUTO3, AUTO4, AUTO5, AUTO6NG, AUTO8, AUTO9) targeting additional hematologic malignancies, solid tumors, and autoimmune indications including systemic lupus erythematosus and progressive multiple sclerosis.

Autolus generates revenue primarily through sales of AUCATZYL to certified treatment centers and hospital networks in the United States, United Kingdom, and European Union. FY2025 net product revenue was $74.3M, growing to $26.2M in Q1 2026 (versus $9.0M in Q1 2025), with 2026 full-year guidance of $120-135M. Manufacturing is anchored at the Nucleus, a 70,000 sq ft commercial facility in Stevenage, UK, designed for approximately 2,000 batches per year (with capacity doubling planned for 2026), supported by wholly-owned operating subsidiaries in the United States (Autolus Inc., Delaware/Gaithersburg), United Kingdom (Autolus Limited, England), and Germany (Autolus GmbH, Weil am Rhein). The company supplements direct sales with the AutolusAssist U.S. patient support program covering travel, housing, and meal logistics.

Since founding in 2014 with a £30M Series A from Syncona, Autolus has progressed through Series B (£40M, 2016), Series C ($80M, 2018), a NASDAQ IPO in June 2018 ($160.4M), and multiple subsequent public offerings (totaling several hundred million dollars through 2024), supplemented by strategic capital from Blackstone Life Sciences (up to $250M announced in 2021) and a 2024 CAR T collaboration with BioNTech. As of April 2026, the company initiated a 13% workforce reduction to save $15M annually beginning in 2027 alongside $8M of restructuring charges, reflecting a focus on operational efficiency as commercial ramp accelerates.

Name

Autolus

Legal name

Autolus Therapeutics plc

Website

https://autolus.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

CAR T Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

akta.pro secondary industry

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

Keywords

• CAR T cell therapy
• Autologous cell therapy
• Oncology biopharmaceuticals
• T cell programming
• Cell therapy manufacturing

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Subscription Recurring: No source material with WX-format source IDs was provided to support revenue model details.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Autolus develops, manufactures, and commercializes autologous CAR T cell therapies for cancer and autoimmune diseases. Its lead and only currently approved product is AUCATZYL (obecabtagene autoleucel / obe-cel), a CD19-directed CAR T cell therapy approved by the US FDA in 2024 and subsequently by the UK MHRA and European Commission in 2025 for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. The company also advances a pipeline of next-generation CAR T product candidates (AUTO1/22, AUTO3, AUTO4, AUTO5, AUTO6NG, AUTO8, AUTO9) targeting hematologic malignancies, T-cell lymphomas, solid tumors, and autoimmune indications, supported by an in-house commercial-scale manufacturing facility, The Nucleus, in Stevenage, UK.

Product overview

Autolus Therapeutics is a clinical-to-commercial biopharmaceutical company built around a single unified advanced cell programming platform that powers a portfolio of autologous CAR T cell therapy candidates. The only commercially approved product is AUCATZYL (obecabtagene autoleucel, also known as obe-cel), a CD19-directed CAR T therapy for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL), which received US FDA approval in 2024 and subsequent UK MHRA conditional marketing authorization and European Commission approval in 2025, with UK commercial launch in January 2026. The same platform is extended across a pipeline of next-generation product candidates: AUTO1/22 and AUTO3 (dual CD19/CD22 targeting for B-cell malignancies), AUTO4 and AUTO5 (TRBC1- and TRBC2-targeting for T-cell lymphoma), AUTO6NG (GD2 targeting for neuroblastoma), AUTO8 (dual BCMA/CD19 targeting for multiple myeloma), and AUTO9 (preclinical AML candidate), with obe-cel additionally being evaluated in systemic lupus erythematosus. Together, AUCATZYL forms the approved commercial anchor while AUTO1/22, AUTO3, AUTO4, AUTO5, AUTO6NG, AUTO8, and AUTO9 represent the modular pipeline extensions of Autolus's core CAR T cell programming technology.

Differentiator

Problem solved

Functional benefit

Brands

• AUCATZYL: Autolus' approved autologous CD19 CAR T-cell therapy (obecabtagene autoleucel / obe-cel) for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
• Obe-cel
• AUTO1/22
• AUTO4 and AUTO5
• AUTO6NG
• AUTO8
• The Nucleus
• AutolusAssist

Products and services

• AUCATZYL (obecabtagene autoleucel; obe-cel) Autologous CD19-directed CAR T cell therapy approved by the US FDA (2024), UK MHRA (2025 conditional marketing authorisation), and European Commission (2025) for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (B-ALL); commercially launched in the UK in January 2026. Obe-cel is also being evaluated for indication expansion including systemic lupus erythematosus (SLE).
• AUTO1/22 Dual-targeting CD19/CD22 CAR T cell therapy candidate in Phase 1 development for pediatric relapsed/refractory B-cell ALL, designed to reduce antigen-negative relapse by simultaneously engaging both CD19 and CD22 on B-cell malignancies.
• AUTO3 Dual-targeting CD19/CD22 CAR T cell therapy candidate in development for B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL), leveraging Autolus's advanced cell programming platform.
• AUTO4 TRBC1-targeting CAR T cell therapy candidate in development for T-cell malignancies, including peripheral T-cell lymphoma (PTCL), using a T-cell receptor beta chain constant region 1 (TRBC1) approach to selectively target malignant T-cell clones.
• AUTO5 TRBC2-targeting CAR T cell therapy candidate in development for T-cell lymphoma, complementing AUTO4 by targeting the TRBC2-positive T-cell population.
• AUTO6NG GD2-targeting CAR T cell therapy candidate in development for neuroblastoma and other GD2-expressing solid tumors (MAGNETO Phase 1), incorporating next-generation enhancements to Autolus's advanced cell programming platform.
• AUTO8 Dual-targeting BCMA/CD19 CAR T cell therapy candidate in development for multiple myeloma, intended to address BCMA antigen escape by simultaneously targeting CD19.
• AUTO9 Preclinical CAR T cell therapy candidate in development for acute myeloid leukemia (AML), expanding Autolus's platform into myeloid malignancies.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves10 records

Expansion highlights6 records

Emerging players

• Cellectis: Clinical-stage allogeneic CAR T developer using TALEN gene editing, with multiple programs in B-ALL and other hematologic malignancies overlapping with Autolus's pipeline.
• 2seventy bio: Cell therapy company co-marketing Abecma (idecabtagene vicleucel) with BMS and continuing CAR T pipeline work; operates a similar autologous cell therapy commercial model to Autolus.
• Caribou Biosciences: Clinical-stage allogeneic CAR T developer using CRISPR-based gene editing; overlapping target indications (B-ALL, B-NHL) with Autolus and a potential longer-term modality competitor.
• Allogene Therapeutics: Pioneering allogeneic ('off-the-shelf') CAR T cell therapies targeting CD19 and BCMA; if successful, would represent a modality-level competitive threat to Autolus's autologous CAR T platform.
• Beam Therapeutics: Developing base-edited CAR T cell therapies for hematologic malignancies and rare diseases; an emerging modality competitor to Autolus's engineered T-cell platform.
• CRISPR Therapeutics: Developing gene-edited allogeneic CAR T cell therapies (e.g., CTX112 for CD19) with partners Vertex and Roche; represents a next-generation competitive modality to Autolus's autologous constructs.

Direct peers

• Bristol Myers Squibb: Markets Breyanzi (CD19 CAR T) and Abecma (BCMA CAR T) following the Celgene/Juno acquisitions, directly overlapping Autolus's CD19 and pipeline BCMA (AUTO8) franchises; deep commercial reach into US treatment centers.
• Gilead Sciences (Kite Pharma): Markets Yescarta and Tecartus, the leading commercial CD19 CAR T cell therapies, in direct competition with Autolus's AUCATZYL in B-cell hematologic malignancies; same autologous CAR T modality, same customer base of academic treatment centers.
• Johnson & Johnson (Janssen): Co-markets Carvykti (ciltacabtagene autoleucel) with Legend Biotech for multiple myeloma, directly competing with Autolus's AUTO8 BCMA/CD19 program; large pharma with global commercialization capability.
• Novartis: Pioneer of CAR T cell therapy with Kymriah (tisagenlecleucel), the first FDA-approved CAR T, directly competing with AUCATZYL in B-ALL and DLBCL; broad biopharma with deep commercial and manufacturing infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/autolus-ltd-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles31 records

Subsidiaries3 records

Funding overview

Funding rounds10 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Autolus